
NeoGenomics (NEO) Stock Forecast & Price Target
NeoGenomics (NEO) Analyst Ratings
Bulls say
NeoGenomics Inc has demonstrated a solid financial performance with an adjusted gross margin of 46.8%, reflecting a year-over-year increase of 150 basis points, alongside an adjusted EBITDA margin of 4.2%, which rose 200 basis points and exceeded consensus expectations. The company also reported a revenue per test growth of 2.7%, increasing from $447 to $459 in the fourth quarter of 2024, influenced by pricing strategies, revenue cycle management, and the mix of next-generation sequencing (NGS) tests. Furthermore, NGS testing experienced significant growth of 18% in the first quarter of 2025, indicating a positive trend in demand for advanced oncological diagnostic services.
Bears say
NeoGenomics Inc. is facing significant challenges, as evidenced by its recent non-clinical revenue performance, which totaled $18.3 million, falling short of the $20.9 million consensus estimate and reflecting a decline of 15.6% from prior growth. This decrease, contrasting sharply with the previous 4.4% growth in 4Q24, indicates a troubling slowdown in overall revenue growth, compounded by underlying macroeconomic issues. Furthermore, the company is exposed to risks such as potential setbacks in reimbursement processes, increased competition, and the financial impact of necessary reinvestments, all of which could further erode EBITDA margins and market positioning.
This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.
NeoGenomics (NEO) Analyst Forecast & Price Prediction
Start investing in NeoGenomics (NEO)
Order type
Buy in
Order amount
Est. shares
0 shares